Get the Stockscreener App
491.49
0.86%
4.17
After Hours:
498.50
7.01
+1.43%
Madrigal Pharmaceuticals Inc stock is traded at $491.49, with a volume of 316.58K.
It is up +0.86% in the last 24 hours and down -2.03% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$487.32
Open:
$486.71
24h Volume:
316.58K
Relative Volume:
0.98
Market Cap:
$11.16B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-19.57
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
+2.18%
1M Performance:
-2.03%
6M Performance:
+25.56%
1Y Performance:
+44.61%
1-Day Range:
$480.00
$498.10
1-Week Range:
$458.07
$498.10
52-Week Range:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
491.49 | 11.07B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.31 | 121.26B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
792.16 | 83.89B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
845.35 | 52.20B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.68 | 44.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
359.05 | 39.27B | 4.98B | 69.60M | 525.67M | 0.5198 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal earnings up next: Can Rezdiffra momentum offset losses? - Investing.com UK
Earnings Preview For Madrigal Pharmaceuticals - Benzinga
Madrigal’s $50M Pfizer deal sparks a new MASH drug power play - MSN
John Paulson's Strategic Moves: Madrigal Pharmaceuticals Inc. Sees a -3.09% Impact - GuruFocus
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday - Seeking Alpha
Madrigal Pharmaceuticals secures global licensing agreement - Pennsylvania Business Report -
Madrigal Pharmaceuticals signs global siRNA licensing deal with Ribo - MSN
Madrigal doubles down on MASH with a $4.4 billion licensing deal with China’s Ribo - MSN
Madrigal Pharmaceuticals Signs Global siRNA Licensing Deal With Ribo - MyChesCo
What to Expect From These Drug/Biotech Players This Earnings Season? - bitget.com
What is the dividend yield of Madrigal Pharmaceuticals IncEarnings Recap Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
IPO Launch: What is the dividend yield of Madrigal Pharmaceuticals IncJuly 2025 Highlights & Weekly Stock Breakout Alerts - baoquankhu1.vn
Stock Report: How correlated is Madrigal Pharmaceuticals Inc to the S P500Weekly Trade Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility - Yahoo Finance
Principal Financial Group Inc. Purchases 2,862 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
(MDGL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Aug Spikes: Is Madrigal Pharmaceuticals Inc stock a value trapMarket Movement Recap & AI Optimized Trade Strategies - baoquankhu1.vn
How Madrigal Pharmaceuticals Inc. (YDO1) stock stacks up against competitors2025 Retail Activity & Daily Market Momentum Tracking - mfd.ru
Why Madrigal Pharmaceuticals Inc. stock is seen as undervaluedWeekly Investment Report & Scalable Portfolio Growth Methods - mfd.ru
Madrigal Pharmaceuticals is Now Oversold (MDGL) - Nasdaq
What are Madrigal Pharmaceuticals Inc.’s recent SEC filings showingMarket Risk Summary & Daily Stock Trend Reports - mfd.ru
MDGL Strengthens MASH Franchise With New Genetic Approaches - Finviz
Madrigal expands MASH pipeline in $4.4bn siRNA licensing deal - Yahoo Finance
Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Madrigal grants equity to new hires as MASH drug momentum builds - MSN
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Madrigal expands its MASH pipeline via Ribo deal - The Pharma Letter
Madrigal Pharmaceuticals (MDGL) to Release Earnings on Thursday - MarketBeat
Madrigal Pharmaceuticals Expands Team With Equity Awards to New Hires - MSN
Madrigal expands MASH pipeline with siRNA therapies in $4.4 B deal - BioSpectrum Asia
Suzhou Ribo Life Science Signs Global siRNA Licensing Deal With Madrigal Pharma; Shares Rise 7% - marketscreener.com
What are analysts’ price targets for Madrigal Pharmaceuticals Inc.Price Action & Low Risk Growth Stock Ideas - mfd.ru
Is Madrigal Pharmaceuticals Inc. in a long term uptrendJuly 2025 Retail & Trade Opportunity Analysis Reports - mfd.ru
Madrigal Continues Building Out MASH Pipeline With Ribo Life Science Deal - Citeline News & Insights
What is Madrigal Pharmaceuticals Inc. s revenue forecastJuly 2025 Update & Accurate Trade Setup Notifications - mfd.ru
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH - Finviz
Madrigal builds in MASH with $4.4bn+ Ribo alliance - pharmaphorum
Madrigal Pharmaceuticals (MDGL) Secures $4.46B Licensing Deal wi - GuruFocus
Madrigal licenses six Ribo siRNA programs - BioWorld MedTech
Madrigal inks licensing deal for MASH drugs (MDGL:NASDAQ) - Seeking Alpha
Madrigal expands its MASH pipeline with exclusive global licensing agreement for six preclinical siRNA programs - marketscreener.com
Ribo Life Science Enters Exclusive Licensing Agreement with Madrigal Pharmaceuticals - Intellectia AI
Madrigal, China's Suzhou Ribo sign license deal for liver-disease programs - marketscreener.com
Madrigal turns to RNAi drugs from China to bolster MASH pipeline - Yahoo Finance
Madrigal, Suzhou Ribo in license deal for liver-disease programs - marketscreener.com
Madrigal Pharmaceuticals (MDGL) Secures Global License for siRNA Programs - GuruFocus
Madrigal Pharmaceuticals, Inc. announced an exclusive global licensing agreement to introduce six preclinical-stage siRNA (small interfering RNA) programs, aiming to significantly expand its research and development pipeline for metabolic dysfunction-asso - Bitget
Madrigal Pharmaceuticals Expands MASH Pipeline with Exclusive License for siRNA Programs - Quiver Quantitative
Madrigal bets on gene-silencing MASH drugs in deal worth up to $4.4B - Stock Titan
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):